Multiple Sclerosis, COVID-19 and Vaccines: Making the Point | Neurology and Therapy
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis | The BMJ
Covid autumn booster vaccine 2023: Everything you need to know - Department of Health and Social Care Media Centre
Factsheet: COVID-19 Vaccine Guidance for People Living with Multiple Sclerosis (English, Spanish) | Vaccine Resource Hub
MS Patients on Anti-CD20 Therapy May Benefit from COVID Booster
Vaccination and immunotherapies in neuroimmunological diseases | Nature Reviews Neurology
Covid Autumn Booster Vaccine Information (2023) - The ME Association - The ME Association
MS and COVID-19 Vaccines - Advice & Support | MS Society
Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis | Neurology and Therapy
COVID-19 4th Booster For Chronic Conditions at HHMP
Response to COVID-19 boosters in seronegative multiple sclerosis patients
Breakthrough COVID-19 in Patients With Multiple Sclerosis: Snapshot From One Data Registry – Consult QD
New Data Show COVID-19 Vaccine Does Not Raise Stroke Risk
MS Patients Respond to Pfizer, Moderna Booster Shots
Queen Mary University of London
Vaccines | Free Full-Text | Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Vaccines | Free Full-Text | Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients - ScienceDirect
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis | Journal of Neurology, Neurosurgery & Psychiatry
T-cell response to Omicron after an mRNA COVID vaccine booster
COVID-19 | Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod | springermedizin.de
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study - ScienceDirect
